New tetanus shot under study in 10,000 people
NCT ID NCT07107932
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large real-world study is testing an injection called siltartoxatug (Sintetol®) to prevent tetanus in people who have been injured. Researchers will follow 10,000 participants for 90 days to see if the shot prevents tetanus and to track any side effects. The goal is to learn how well this treatment works in everyday medical settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
siltartoxatug injection (Sintetol®)
What this could lead to
If successful, this could confirm siltartoxatug as a safe and effective way to prevent tetanus after an injury, potentially replacing current treatments.
What could go wrong
This is an observational registry, not a controlled trial, so results may be less definitive. Side effects are possible, and the study does not compare siltartoxatug to other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TETANUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shaoxing Central Hospital
RECRUITINGShaoxing, Zhejiang, 312030, China
Contact Phone: •••-•••-••••
-
The Second Affiliated Hospital of Shantou University
NOT_YET_RECRUITINGShantou, Guangdong, 515041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xiangyun County People's Hospital
NOT_YET_RECRUITINGXiangyun, Yunnan, 672100, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhoushan Putuo District People's Hospital
NOT_YET_RECRUITINGZhoushan, Zhejiang, 316100, China
Contact Phone: •••-•••-••••